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The APTIMA COMBO 2 assay, which detects and amplifies rRNA from Chlamydia trachomatis and/or
Neisseria gonorrhoeae, is approved for use on ThinPrep liquid-based Pap test specimens. The objective was to
determine the clinical utility of the APTIMA assays (APTIMA COMBO 2 assay, APTIMA CT assay for
Chlamydia trachomatis, and APTIMA GC assay for Neisseria gonorrhoeae) for screening women during their
annual Pap exam, using SurePath liquid-based Pap test specimens. Two cervical samples were collected from
1,615 females attending six clinical sites in North America. A cervical broom sample was processed for cytology,
with the residuum aliquoted into an APTIMA specimen transfer kit tube. The second cervical swab sample was
put into APTIMA specimen transport medium, and both samples were tested with each APTIMA assay on a
direct sampling system. Using a subject-infected status that utilized cervical-swab specimen results from two
APTIMA assays, the prevalence was 7.9% for Chlamydia trachomatis and 2.5% for N. gonorrhoeae. For the
liquid-based Pap samples, the sensitivities, specificities, positive predictive values, and negative predictive
values for Chlamydia trachomatis detection were 85.2%, 99.5%, 93.2%, and 98.7%, respectively, for the APTIMA
COMBO 2 assay and 89.1%, 98.7%, 85.7%, and 99.1%, respectively, for the APTIMA CT assay. For N.
gonorrhoeae detection, the values were 92.5%, 100%, 100%, and 99.8%, respectively, for the APTIMA COMBO
2 assay and 92.5%, 99.9%, 97.4%, and 99.8%, respectively, for the APTIMA GC assay. The high predictive values
support the use of the assays with SurePath liquid-based Pap specimens processed with the APTIMA specimen
transfer kit.
Annual screening for cervical abnormalities using a Pap
test has resulted in a substantial reduction in morbidity and
mortality from cervical cancer (11). There are three liquid-
based Pap tests (LPTs) approved by the United States Food
and Drug Administration (FDA): PreservCyt ThinPrep (Cy-
tyc, Boxborough, MA), SurePath (TriPath Care Technolo-
gies, Burlington, NC), and Cytotek MonoPrep (Monogen,
Inc., Vernon Hills, IL). Liquid-based cytology has provided
greater Pap testing accuracy, and the sample may serve as a
specimen to test for infectious agents, such as human pap-
illomavirus (2, 11), Chlamydia trachomatis (5, 14), and Neis-
seria gonorrhoeae (6, 9). The APTIMA COMBO 2 assay,
APTIMA CT assay for Chlamydia trachomatis, and AP-
TIMA GC assay for Neisseria gonorrhoeae are transcription-
mediated amplification tests that utilize target capture spec-
imen processing for the in vitro qualitative detection of
rRNA from C. trachomatis and/or N. gonorrhoeae. The as-
says are approved for use on cervical swab (CS) samples,
vaginal swab samples, urethral swab samples, and first-catch
urine samples. The APTIMA COMBO 2 assay is approved
for use with ThinPrep LPT specimens. A limited number of
studies have been published using both amplified and
nonamplified tests for C. trachomatis or N. gonorrhoeae in
liquid-based specimens and have concentrated on the use of
ThinPrep samples (1, 5–10; D. Fuller, T. Davis, and J. Tal-
bott, unpublished data). Our objective was to determine the
clinical utility of the APTIMA assays (Gen-Probe Incorpo-
rated) for screening women for C. trachomatis and N. gon-
orrhoeae during their annual Pap examination by using Sure-
Path LPT specimens.
MATERIALS AND METHODS
A total of 1,615 female subjects signed consent forms while being enrolled
during 2004 at six clinical sites in North America: University of North Carolina
(UNC), Chapel Hill, NC; University of Alabama (UAB), Birmingham, AL; St.
Joseph’s Healthcare (SJH), Hamilton, ON, Canada; University of Oklahoma—
Tulsa (UOT), Tulsa, OK; University of Illinois—Urbana (UIU), Urbana, IL; and
Planned Parenthood of Minnesota/South Dakota (MNSD), St. Paul, MN. Each
patient had a cervical broom collection into a SurePath preservative-fluid tube,
which was processed for cytology. The residual specimen was transferred to an
APTIMA specimen transfer tube and tested with each APTIMA assay. A CS
sample was also collected by using the APTIMA collection kit. For each assay,
the results on the SurePath specimen were compared to a subject-infected status
where the patient’s CS sample was positive by two APTIMA assays (APTIMA
COMBO 2 and APTIMA CT and APTIMA COMBO 2 and APTIMA GC).
Sensitivity, specificity, and predictive values were computed based on binomial
distribution. Fisher’s exact test was used to calculate P values, and 95% confi-
dence intervals were calculated. The patient’s age, ethnic origin, and reason for
clinic visit were recorded. To determine the performance of the APTIMA
COMBO 2, APTIMA CT, and APTIMA GC assays on LPT specimens, positives,
negatives, false positives, and false negatives were calculated.
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RESULTS
Table 1 is a summation of the information gathered on
the questionnaire and shows that the overall mean age of the
women enrolled in the study was 29.6 years. Patients from the
SJH site were younger (19.9 years) and from the UIU site
older (37.8 years). Ethnicity or race varied among sites. The
UIU and MNSD patients were predominantly white non-His-
panic women (93.1% and 87.1%, respectively), whereas those
from UAB were predominantly black non-Hispanic women
(91.9%). Women enrolled at the UNC site were 75% black
non-Hispanic and 25% white non-Hispanic. At SJH, these
percentages were 23.6% and 60%, respectively. The UOT en-
rollment had a more even distribution of the three predomi-
nant combinations. The UAB and UNC women were attend-
ing for sexually transmitted disease (STD) screening, whereas
the other four study sites reported that most were attending
the clinic for an annual examination. Overall, 71.1% (1,148/
1,615) of the women were without symptoms. The majority of
patients attending for their annual examination were asymp-
tomatic compared to those attending for STD screening.
Table 2 shows the numbers of patients enrolled at each
study site, varying from 20 from UNC to 465 at UOT. Of the
1,615 women enrolled, 113 were infected only with C. tra-
chomatis, 15 with both C. trachomatis and N. gonorrhoeae,
and 25 with only N. gonorrhoeae. A total of 20 patients were
positive in the APTIMA CT assay but negative by APTIMA
COMBO 2, and 3 were positive by APTIMA COMBO 2 but
negative in the APTIMA CT test. One woman’s CS sample
was positive in the APTIMA GC test but negative in the
APTIMA COMBO 2 assay. Overall, the prevalence of in-
fection was 7.9% (128/1,615) for C. trachomatis (confidence
interval [CI], 6.7 to 9.45) and 2.5% (40/1,615) for N. gonor-
rhoeae (CI, 1.8 to 3.45). The prevalence of C. trachomatis
infections ranged from 0.9% at UIU to 17.0% at SJH. N.
gonorrhoeae infections were most prevalent at UAB (7.4%)
and not prevalent at UIU and UNC.
Table 3 summarizes the results of testing the CS samples for
C. trachomatis and N. gonorrhoeae using the APTIMA
COMBO 2, APTIMA CT, and APTIMA GC assays, according
to the presence or absence of symptoms. Infection with C.
trachomatis was diagnosed in 52 (11.1%) of 467 symptomatic
patients, compared to 76 (6.6%) of 1,148 patients without STD
symptoms (P  0.003); N. gonorrhoeae was diagnosed in 17
(3.6%) and 23 (2.0%) of symptomatic and asymptomatic pa-
tients, respectively (P  0.075).
The calculation of the agreement of results of testing CS and
LPT samples using the APTIMA COMBO 2 assay was per-
formed for C. trachomatis detection and showed positive
agreement (PA) of 78.2% (65.0 to 88.2%), negative agreement
(NA) of 99.5% (98.3 to 99.9%), and overall agreement (OA) of
97.0% (95.0 to 98.4%) in symptomatic patients, compared to
PA of 86.8% (77.1 to 93.5%), NA of 99.5% (98.9 to 99.8%),
and OA of 98.6% (97.7 to 99.2%) in asymptomatic patients.
The respective results for N. gonorrhoeae detection for the two
specimen types with the APTIMA COMBO 2 assay were PA of
88.2% (63.6 to 98.5%), NA of 100% (99.2 to 100%), and OA
of 99.6% (98.5 to 99.9%) in patients with symptoms, compared
to PA of 95.7% (78.1 to 99.9%), NA of 100% (99.7 to 100%),
and OA of 99.9% (99.5 to 100%) in those that were asymp-
tomatic.
The prevalences, sensitivities, specificities, positive predic-
tive values (PPV), and negative predictive values (NPV) for C.
trachomatis and N. gonorrhoeae determined by testing the
LPT samples in the assays are summarized in Table 4. The
APTIMA COMBO 2 assay performed on the LPT samples
detected 109 of the 128 CS sample-positive patients (85.2%).
The APTIMA CT assay performed on the LPT sample de-
tected 114 of the positives (89.1%). The APTIMA CT assay
recorded 19 (1.1%) extra positives and 14 (0.8%) extra nega-
tives. The APTIMA COMBO 2 test detected 8 (0.5%) extra
positives and 19 (1.2%) extra negatives. The percent sensitiv-
ities of the APTIMA COMBO 2 and APTIMA CT assays for
the detection of C. trachomatis-infected women by testing the
TABLE 1. Ethnic origin, symptom status, and reason for clinic visit of women from the six study sites collecting liquid-based Pap samples
Clinic site Mean age(yr)











UIU 37.8 13 (3.9) 4 (1.2) 311 (93.1) 283 (84.7) 3 (0.9) 325 (97.3)
MNSD 27.4 7 (3.6) 5 (2.6) 169 (87.1) 165 (85.1) 25 (12.9) 180 (92.8)
SJH 19.9 46 (23.6) 6 (3.1) 117 (60.0) 146 (74.9) 40 (20.5) 157 (80.5)
UOT 30.8 64 (13.8) 181 (38.9) 186 (40.0) 319 (68.6) 6 (1.3) 361 (77.6)
UAB 27.1 374 (91.9) 0 (0) 28 (6.9) 5 (1.2) 349 (85.7) 117 (28.7)
UNC 28.1 15 (75) 0 (0) 5 (25.0) 0 (0) 18 (90) 8 (40.0)
Total 29.6 519 (32.1) 196 (12.1) 816 (50.5) 918 (56.8) 441 (27.3) 1,148 (71.1)
TABLE 2. Numbers of single and dual infections with C. trachomatis
and/or N. gonorrhoeae determined by positive results using APTIMA
COMBO 2, APTIMA CT, and APTIMA GC assays performed
on CS samples of 1,615 women at six study sitesa
Site No. ofpatients
No. (%) with infection status of: Total no. (%)infected with:
CT GC CT GC CT GC CT GC
UIU 334 3 (0.9) 0 (0) 0 (0) 3 (0.9) 0 (0.0)
MNSD 194 7 (3.6) 0 (0) 1 (0.5) 7 (3.6) 1 (0.5)
SJH 195 31 (15.9) 2 (1.0) 4 (2.1) 33 (17.0) 6 (3.1)
UOT 465 22 (4.7) 2 (0.4) 1 (0.2) 24 (5.2) 3 (0.6)
UAB 407 49 (12.0) 11 (2.7) 19 (3.4) 60 (14.7) 30 (7.4)
UNC 20 1 (5.0) 0 (0) 0 (0) 1 (5.0) 0 (0.0)
Total 1,615 113 (6.9) 15 (0.9) 25 (1.5) 128 (7.9) 40 (2.5)
a CT, C. trachomatis; GC, N. gonorrhoeae.
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liquid-based Pap samples ranged from 75% at UOT to 100% at
three of the six study sites (data not shown). Table 4 also shows
that the specificities of the APTIMA COMBO 2, APTIMA
CT, and APTIMA GC assays were very high (98.7 to 100%).
The specificities did not vary significantly from site to site (P 
0.003). In testing LPT specimens, the percent sensitivities and
specificities, respectively, by site for the detection of C. tracho-
matis were 100 and 100 at UIU, 100 and 100 at MNSD, 82.3
and 96.9 at SJH, 75.0 and 99.8 at UOT, 86.7 and 99.7 at UAB,
and 100 and 100 at UNC using the APTIMA COMBO 2 test.
The percent values with the APTIMA CT test were 100 and
99.7, 100 and 99.5, 87.9 and 93.8, 83.3 and 99.5, 90.0 and 98.6,
and 100 and 100 at each respective site. Overall, the PPV and
NPV were 93.2% and 98.7% using the APTIMA COMBO 2
test and 85.7% and 99.1% when the APTIMA CT assay was
used to diagnose C. trachomatis infections. From site to site,
the NPV for both tests showed a tight range between 96.9 and
100%, with three of the sites at 100% (data not shown). The
three sites with the NPV at 100% also demonstrated their PPV
at 100%. UAB and UOT demonstrated strong PPV and NPV,
in the mid- to high 90% range. The SJH site recorded the
lowest PPV, at 84.8% with the APTIMA COMBO 2 test and
76.3% for the APTIMA CT assay.
Calculations of the sensitivities, specificities, and predictive
values for N. gonorrhoeae are also summarized in Table 4. By
APTIMA COMBO 2 testing of the LPT sample, the overall
prevalence of N. gonorrhoeae infections was 2.3%, ranging
from 0% at UIU and UNC to 3.1% at SJH (data not shown),
and 92.5% of the CS samples positive for N. gonorrhoeae were
detected by both the APTIMA COMBO 2 and APTIMA GC
assays. PPV and specificity were 100% overall and at each of
the study sites. Sensitivity was 100% at three of the four sites
where N. gonorrhoeae was found, with only three extra nega-
tives by APTIMA COMBO 2 and APTIMA GC reported at
UAB (sensitivity, 90%). The values reported for the APTIMA
GC assay were equally impressive for sensitivity, specificity,
PPV, and NPV, with consistent reporting from site to site.
DISCUSSION
To our knowledge, this is the first publication on the use of
the APTIMA assays (APTIMA COMBO 2, APTIMA CT, and
TABLE 3. Numbers of C. trachomatis and N. gonorrhoeae infections according to the presence or absence of symptoms from 1,615 patients
whose CS samples were tested using the APTIMA COMBO 2, APTIMA CT, and APTIMA GC assaysa
Infection status








for: Asymptomatic for: CT GC
CT GC CT GC
Infectedb
CT    52 76 7.9 (6.7–9.45)
GC    17 23 2.5 (1.8–3.45)
Noninfected
CT    406 1,058
GC    449 1,125
Noninfected
CT    6 14
GC   1 0
Noninfected
CT    3 0
GC    0 0
Total 467 467 1,148 1,148
a CT, C. trachomatis; GC, N. gonorrhoeae.
b CS sample positive for C. trachomatis or N. gonorrhoeae in two tests.
TABLE 4. Performance of APTIMA COMBO 2, APTIMA CT, and APTIMA GC assays on 1,615
















C. trachomatis APTIMA COMBO 2 109 (6.7) 8 1,479 19 85.2 (77.8–90.8) 99.5 (99.0–99.8) 93.2 98.7
APTIMA CT 114 (7.1) 19 1,468 14 89.1 (82.3–93.9) 98.7 (981–99.3) 85.7 99.1
N. gonorrhoeae APTIMA COMBO 2 37 (2.3) 0 1,575 3 92.5 (79.6–98.4) 100 (99.8–100) 100 99.8
APTIMA GC 37 (2.3) 1 1,574 3 92.5 (79.6–98.4) 99.9 (99.6–100) 97.4 99.8
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APTIMA GC) to detect women infected with C. trachomatis
and/or N. gonorrhoeae by testing the residuum from a SurePath
liquid-based Pap collection. Our study involved a substantial
number (n  1,615) of women from six different geographical
regions in North America, with a range of races and ethnicities,
seeking either an annual pelvic examination or screening for a
sexually transmitted infection. Although the majority of
women screened were asymptomatic, 41.1% (69/168) of the
infected women had symptoms (Table 3). Performance of the
APTIMA assays for C. trachomatis demonstrated very high
specificities and NPV (Table 4). The PPV were 93.2% for the
APTIMA COMBO 2 assay and 85.7% for the APTIMA CT
assay. The NPV for C. trachomatis were 98.7% for the
APTIMA COMBO 2 assay and 99.1% for the APTIMA CT
assay. One of the study sites accounted for seven of the false
positives, suggesting that the results may have been influenced
by technical difficulties in processing the samples or collection
of the LPT sample. Examination of these hypotheses is under
way. These observations may also be a reflection of the exquis-
ite analytical sensitivity of the APTIMA assays (3, 4), which
allows for the detection in samples of small amounts of the
target nucleic acid, near the assay cutoffs (12). This observation
with C. trachomatis has not been observed for N. gonorrhoeae
and may be a reflection of the APTIMA COMBO 2 and
APTIMA GC assays having lower analytical sensitivities for
the gonococcus than for C. trachomatis or of a consistently
higher level of N. gonorrhoeae than C. trachomatis in clinical
specimens.
Although the number of N. gonorrhoeae infections was
lower, both the APTIMA COMBO 2 and APTIMA GC assays
were highly sensitive and specific for it. The PPV and NPV
ranged from 97.4 to 100% (Table 4). Previous studies to de-
termine whether liquid-based Pap specimens might be suitable
for the detection of C. trachomatis or N. gonorrhoeae have used
direct fluorescent antibody staining, AMPLICOR PCR, or the
ligase chain reaction (LCR) test on PreservCyt ThinPrep sam-
ples. A study by Inhorn et al. (8) compared the results of C.
trachomatis direct fluorescent antibody staining of ThinPrep
LPT samples to the results for CS smears from 636 women and
reported PA in 43 (6.8%) and discrepant results in 11 (1.7%).
Adjudication of the discrepant results by LCR and PACE 2
nucleic acid hybridization favored the ThinPrep sample (45%)
and the CS smear (55%). The sensitivities at the three study
sites varied from 62.5% to 100%, but the specificities were
consistent across sites. This type of variation from site to site
was also observed in our study and emphasizes the need to
train both microbiology and cytology technologists in handling
the dual-testing protocols. Hopwood et al. (7), testing CS and
ThinPrep samples, showed 100% concordance of 19 LCR pos-
itives and 562 negatives, which were stable for 5 months. Kou-
mans et al. (9) tested ThinPrep samples from 255 sexually
active adolescent women, using LCR for C. trachomatis and N.
gonorrhoeae, and also performed other forms of testing on
urine and CS samples (LCR for C. trachomatis and N. gonor-
rhoeae, PCR for C. trachomatis and N. gonorrhoeae, transcrip-
tion-mediated amplification for C. trachomatis, and culture),
which broadened the reference standard for comparison of
tests and samples to diagnose infected patients. They reported
strong agreement (0.97) for C. trachomatis between LCR on
ThinPrep and LCR on CS samples collected into the kit trans-
port medium (kappa, 0.92, where kappa is a statistical mea-
surement of interobserver agreement which compensates and
corrects for the proportion of agreement that might be due to
chance); for N. gonorrhoeae the agreement was 0.99 (kappa,
0.96). The sensitivity of LCR on the liquid-based Pap sample
was higher for detection of C. trachomatis (93%) than for N.
gonorrhoeae (81%). In contrast to the ThinPrep studies of
Koumans, we found that with SurePath specimens, the N.
gonorrhoeae assays were more sensitive (APTIMA COMBO 2,
92.5%, and APTIMA GC, 92.5%) than the C. trachomatis tests
(APTIMA COMBO 2, 85.2%, and APTIMA CT, 89.1%). The
lower values for C. trachomatis testing of the SurePath liquid-
based Pap samples may have been related to low levels of C.
trachomatis rRNA being present, which may lead to variable
results using multiple tests (13), and to the volume of residuum
available for testing. We did not record volumes routinely, but
Hawthorne et al. (6) showed that the volume of liquid-based
Pap material from a ThinPrep transport tube may impact the
number of reactive samples reported. Using COBAS AMPLI-
COR PCR, they showed that 840 samples with a volume of 5
ml were positive for C. trachomatis in 33 (3.9%) and for N.
gonorrhoeae in 8 (0.9%), compared to 80 samples with a vol-
ume of 5 ml which were negative for both C. trachomatis and
N. gonorrhoeae. Some of these studies have led to Cytyc Cor-
poration seeking FDA approval for AMPLICOR testing of
ThinPrep samples, and Gen-Probe, Inc., recently received clear-
ance from the FDA for APTIMA COMBO 2, APTIMA CT, and
APTIMA GC testing of ThinPrep samples transferred to an LPT.
In a multicenter trial using the APTIMA assays to test Thin-
Prep liquid-based Pap specimens (Fuller et al., unpublished
data), sensitivities and specificities for C. trachomatis (96.7 and
99.3%) and N. gonorrhoeae (92.3 and 99.8%) which were not
influenced by cervical symptoms in 1,626 women were found.
The present study, using SurePath liquid-based Pap samples
for 1,615 women from six centers in North America, showed
some variations in sensitivities and specificities among study
sites for C. trachomatis testing, but the high predictive values
indicate that SurePath liquid-based Pap test residuum could be
used to screen women for C. trachomatis and N. gonorrhoeae in
the APTIMA assays.
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